

63. Alexopoulos D, Dimitropoulos G, Davluros P, et al. Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel: the importance of CYP2C19*2 genotyping. *JACC Cardiovasc Interv* 2011; 4: 403–410.
64. Cuisset T, Frere C, Quilici J, et al. Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study. *JACC Cardiovasc Interv* 2008; 1: 649–653.
65. Akkus NI, Rajpal S, Agnani S. Successful use of glycoprotein IIb/IIIa inhibitor, heparin, and IABP during PCI in a post-neurosurgical patient with STEMI and cardiogenic shock due to very late bare-metal stent thrombosis. *J Invasive Cardiol* 2012; 24: 76–78.
66. Wessler JD, Saldana F, Giugliano RP. Bridging therapy after recent stent implantation: case report and review of data. *Cardiovasc Revasc Med* 2012; 13: 30–38.
67. Alexopoulos D, Pappas C, Sfantou D, et al. Cangrelor in Percutaneous Coronary Intervention: Current Status and Perspectives. *J Cardiovasc Pharmacol Ther* 2018; 23: 13–22.
68. Eisen A, Harrington RA, Stone GW et al. CHAMPION Investigators. Cangrelor compared with clopidogrel in patients with prior myocardial infarction - Insights from the CHAMPION trials. *Int J Cardiol* 2018; 250: 49–55.
69. Selhorst G, Schmidler F, Ott A, et al. Platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor in comparison to clopidogrel: a retrospective pharmacodynamic analysis. *Platelets* 2018; 9: 1–7.
70. Alexopoulos D. Prasugrel resistance: fact or fiction. *Platelets* 2012; 23: 83–90.
71. Samoš M, Fedor M, Kovář F, et al. Prasugrel loading dose in diabetic patients with acute STEMI - Always sufficiently effective? Observation in two cases and review of current knowledge. *Cor et Vasa* 2014; 56: e388–e395.
72. Samoš M, Fedor M, Kovář F, et al. The Impact of Type 2 Diabetes on the Efficacy of ADP Receptor Blockers in Patients with Acute ST Elevation Myocardial Infarction: A Pilot Prospective Study. *J Diabetes Res* 2016; 2016: 2909436.
73. Lemesle G, Schurtz G, Bauters C, et al. High on-treatment platelet reactivity with ticagrelor versus prasugrel: a systematic review and meta-analysis. *J Thromb Haemost* 2015; 13: 931–942.
74. Silvano M, Zambon CF, De Rosa G, et al. A case of resistance to clopidogrel and prasugrel after percutaneous coronary angioplasty. *J Thromb Thrombolysis* 2011; 31: 233–234.
75. Fiore M, Horovitz A, Pons AC, et al. First report of a subacute stent thrombosis in a prasugrel resistant patient successfully managed with ticagrelor. *Platelets* 2014; 25: 636–638.
76. Orban M, Riegger J, Joner M et al. Dual thienopyridine low-response to clopidogrel and prasugrel in a patient with STEMI, cardiogenic shock and early stent thrombosis is overcome by ticagrelor. *Platelets* 2012; 23: 395–398.
77. Musallam A, Lev El, Roguin A. Stent thrombosis in a patient with high on-treatment platelet reactivity despite ticagrelor treatment. *Eur Heart J Acute Cardiovasc Care* 2015; 4: 85–87.
78. Ramotowski B, Žuk A, Budaj A. Repetitive stent thrombosis in a patient with suspected allergy to aspirin and multiple switch between clopidogrel, prasugrel, and ticagrelor. *Kardiologia* 2017; 75: 614.
79. Morgan KP, More RS, Chauhan A. The use of ticagrelor in a patient at increased risk of stent thrombosis resistant to multiple thienopyridines. *Cardiology* 2011; 119: 88–89.

SOLEN MEDICAL EDUCATION

predplatné časopisu Intervenční a akutní kardiologie



MLADÍ LÉKAŘI

50% SLEVA
280 Kč

Fandíme mladým lékařům,
a proto předplatitelé do 35 let získají 50% slevu.

Stačí jen při objednávce
do poznámky uvést rok narození.



TÍŠTĚNÝ ČASOPIS

4 čísla / rok
560 Kč

Přístup k aktuálnímu číslu
na www.iakardiologie.cz

Supplementa a odborné publikace
Aktuální informace o připravovaných kongresech



ELEKTRONICKÁ VERZE

4 čísla / rok
420 Kč

Elektronická verze se slevou 25 %
k zakoupení na www.alza.cz/media

Čtěte nás na počítači nebo
na mobilních zařízeních

OBJEDNÁVEJTE

na webu www.iakardiologie.cz | e-mailem predplatne@solen.cz | telefonem 585 204 335

